Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients
| Status: | Completed |
|---|---|
| Conditions: | Skin Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 127 |
| Updated: | 4/21/2016 |
| Start Date: | July 2009 |
| End Date: | November 2014 |
A Phase II, Double-blind, Randomised Study to Assess the Efficacy of AZD6244 in Combination With Dacarbazine Compared With Dacarbazine Alone in First Line Patients With BRAF Mutation Positive Advanced Cutaneous or Unknown Primary Melanoma
To assess the efficacy in terms of overall survival of AZD6244 in combination with
dacarbazine, compared with dacarbazine alone, in first line patients with BRAF mutation
positive advanced cutaneous or unknown primary melanoma
dacarbazine, compared with dacarbazine alone, in first line patients with BRAF mutation
positive advanced cutaneous or unknown primary melanoma
Inclusion Criteria:
- Histological or cytological confirmation of advanced (inoperable stage III and stage
IV) cutaneous or unknown primary melanoma
- Tumor sample confirmed as BRAF mutation positive
Exclusion Criteria:
- Diagnosis of uveal or mucosal melanoma
- Any prior Investigational therapy comprising inhibitors of Ras, Raf or MEK
- Having received an investigational drug within 30 days of starting treatment, or have
not recovered from side effects of an investigational drug
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials